ERCC2 and neoplasm: In a subset of retrospective clinical-genomic studies of MIBC, patients with somatic ERCC2 mutations were more likely to experience a pathologic complete response (pCR) following cisplatin-based neoadjuvant chemotherapy than patients lacking a tumor ERCC2 mutation (8, 9).